Literature DB >> 18390843

Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells.

Chang-Yeob Han1, Kyoung-Bin Cho, Hong-Seok Choi, Hyo-Kyung Han, Keon-Wook Kang.   

Abstract

The development of multidrug resistance 1 (MDR1) can be mediated by a number of different mechanisms but elevated gene expression of MDR1 (P-glycoprotein) has often been a major cause of chemoresistance in many cancer cells. Therefore, the present study aimed to investigate the role of forkhead box-containing protein, O subfamily (FoxO), transcription factors in regulating the MDR1 gene expression. The proximal promoter region of the human MDR1 contained a putative FoxO-binding site, which partially overlapped with the enhancer/enhancer-binding protein beta-binding region. Gel shift and immunoblot analysis of subcellular fractions revealed that nuclear levels of FoxO1 and its DNA-binding activity were selectively enhanced in MCF-7/ADR cells, which was reversed by a FoxO1 antibody. Reporter gene assays showed that the transcription of MDR1 gene is stimulated by FoxO1 overexpression. Moreover, both MDR1 expression and doxorubicin resistance in MCF-7/ADR cells were reversed by FoxO1 small interfering RNA (siRNA). The MDR1 expression in MCF-7/ADR cells was also inhibited by insulin, a functional FoxO1 inactivator. In conclusion, FoxO1 is a novel transcriptional activator of MDR1 and is crucial for MDR1 induction in MCF-7/ADR cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18390843     DOI: 10.1093/carcin/bgn092

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  33 in total

Review 1.  The "O" class: crafting clinical care with FoxO transcription factors.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

2.  Expression of FOXO1 is associated with GATA3 and Annexin-1 and predicts disease-free survival in breast cancer.

Authors:  Yanyuan Wu; Yayha Elshimali; Marianna Sarkissyan; Hezla Mohamed; Sheila Clayton; Jaydutt V Vadgama
Journal:  Am J Cancer Res       Date:  2011-11-21       Impact factor: 6.166

3.  The forkhead transcription factor FOXO1 mediates cisplatin resistance in gastric cancer cells by activating phosphoinositide 3-kinase/Akt pathway.

Authors:  Jinju Park; Young San Ko; Jiyeon Yoon; Min A Kim; Jong-Wan Park; Woo Ho Kim; Youngsun Choi; Ji Hun Kim; Younghee Cheon; Byung Lan Lee
Journal:  Gastric Cancer       Date:  2013-11-08       Impact factor: 7.370

4.  Nuclear PRMT1 expression is associated with poor prognosis and chemosensitivity in gastric cancer patients.

Authors:  Bolag Altan; Takehiko Yokobori; Munenori Ide; Erito Mochiki; Yoshitaka Toyomasu; Norimichi Kogure; Akiharu Kimura; Keigo Hara; Tuya Bai; Pinjie Bao; Masaki Suzuki; Kyoichi Ogata; Takayuki Asao; Masahiko Nishiyama; Tetsunari Oyama; Hiroyuki Kuwano
Journal:  Gastric Cancer       Date:  2015-10-15       Impact factor: 7.370

5.  Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine.

Authors:  Cheng Li; Dong-Hyun Choi; Jun-Shik Choi
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-01-01       Impact factor: 2.745

6.  Effects of myricetin, an anticancer compound, on the bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats.

Authors:  Cheng Li; Sung-Cil Lim; Jin Kim; Jun-Shik Choi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-03-27       Impact factor: 2.441

Review 7.  FoxO transcription factors in cancer metabolism.

Authors:  Raj Kumar Yadav; Anoop Singh Chauhan; Li Zhuang; Boyi Gan
Journal:  Semin Cancer Biol       Date:  2018-01-05       Impact factor: 15.707

8.  Pygo2 activates MDR1 expression and mediates chemoresistance in breast cancer via the Wnt/β-catenin pathway.

Authors:  Z-M Zhang; J-F Wu; Q-C Luo; Q-F Liu; Q-W Wu; G-D Ye; H-Q She; B-A Li
Journal:  Oncogene       Date:  2016-02-15       Impact factor: 9.867

Review 9.  A fork in the path: Developing therapeutic inroads with FoxO proteins.

Authors:  Kenneth Maiese; Jinling Hou; Zhao Zhong Chong; Yan Chen Shang
Journal:  Oxid Med Cell Longev       Date:  2009 Jul-Aug       Impact factor: 6.543

Review 10.  Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology.

Authors:  Kenneth Maiese; Jinling Hou; Zhao Zhong Chong; Yan Chen Shang
Journal:  ScientificWorldJournal       Date:  2009-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.